loading
Schlusskurs vom Vortag:
$0.67
Offen:
$0.6871
24-Stunden-Volumen:
21,933
Relative Volume:
0.05
Marktkapitalisierung:
$20.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-7.3696
EPS:
-0.0882
Netto-Cashflow:
-
1W Leistung:
+4.75%
1M Leistung:
-7.14%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$0.63
$0.6871
1-Wochen-Bereich:
Value
$0.60
$0.6987
52-Wochen-Spanne:
Value
$0.51
$19.51

Jupiter Neurosciences Inc Stock (JUNS) Company Profile

Name
Firmenname
Jupiter Neurosciences Inc
Name
Telefon
(561) 406-6154
Name
Adresse
1001 NORTH US HWY 1, JUPITER
Name
Mitarbeiter
4
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
JUNS's Discussions on Twitter

Vergleichen Sie JUNS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
JUNS
Jupiter Neurosciences Inc
0.65 20.54M 0 0 0 -0.0882
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.37 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.59 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.82 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.00 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.50 24.70B 3.81B -644.79M -669.77M -6.24

Jupiter Neurosciences Inc Aktie (JUNS) Neueste Nachrichten

pulisher
Apr 21, 2025

Jupiter Neurosciences appoints new auditor amid transition - Investing.com Australia

Apr 21, 2025
pulisher
Apr 08, 2025

Jupiter Neurosciences targets Parkinson’s and longevity markets By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Jupiter Neurosciences Says Co Does Not Anticipate Impact From U.S. Tariffs On Clinical-Stage Prescription Product Development - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Jupiter Neurosciences targets Parkinson's and longevity markets - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Jupiter's Super-Resveratrol Targets Parkinson's Trial and $16.5M NIH Grant - Stock Titan

Apr 08, 2025
pulisher
Mar 28, 2025

Jupiter Neurosciences Inc. (JUNS) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 26, 2025

Jupiter Neurosciences faces NASDAQ delisting over share price By Investing.com - Investing.com India

Mar 26, 2025
pulisher
Mar 25, 2025

Jupiter Neurosciences faces NASDAQ delisting over share price - Investing.com

Mar 25, 2025
pulisher
Mar 18, 2025

Jupiter Neurosciences, Catalent Partner to Produce JOTROL Softgels for Upcoming Trial - Contract Pharma

Mar 18, 2025
pulisher
Mar 07, 2025

Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bluefield Daily Telegraph

Mar 07, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences and Aquanova AG Announce Strategic - GlobeNewswire

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences, Aquanova announce strategic collaboration - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences partners with Aquanova on health products By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan Products - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences partners with Aquanova on health products - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Can Jupiter Neurosciences Capture The $44B Longevity Market With Its New Aquanova Partnership? - StockTitan

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products - Yahoo Finance

Mar 04, 2025
pulisher
Feb 10, 2025

Jupiter Neurosciences Inc (JUNS) Shares Decline Despite Market Challenges - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Jupiter Neurosciences partners with Catalent for Parkinson’s trial By Investing.com - Investing.com Nigeria

Feb 10, 2025
pulisher
Feb 07, 2025

Three technology stocks with differentiated value propositions | 2025-02-07 | Investing News - Stockhouse Publishing

Feb 07, 2025
pulisher
Feb 07, 2025

Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN

Feb 07, 2025
pulisher
Feb 04, 2025

Jupiter Neurosciences Addresses Market Volatility as it - GlobeNewswire

Feb 04, 2025
pulisher
Feb 04, 2025

Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’ - TipRanks

Feb 04, 2025
pulisher
Feb 04, 2025

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - TradingView

Feb 04, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa

Feb 03, 2025
pulisher
Feb 03, 2025

Clinical Trials News Live Feed - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times

Feb 03, 2025
pulisher
Feb 03, 2025

Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

Phase 2a trial of Jotrol as treatment for Parkinson’s planned - Parkinson's News Today

Feb 03, 2025
pulisher
Jan 31, 2025

Jupiter Neurosciences partners with Zina for Parkinson's trial - Investing.com India

Jan 31, 2025
pulisher
Jan 30, 2025

Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study - Marketscreener.com

Jan 30, 2025
pulisher
Jan 30, 2025

Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial - GlobeNewswire

Jan 30, 2025
pulisher
Jan 30, 2025

Jupiter Neurosciences partners with Zina for Parkinson's trial By Investing.com - Investing.com South Africa

Jan 30, 2025
pulisher
Jan 24, 2025

Wall Street Set to Open Slightly Lower Friday as Investors Await PMI, Housing Figures - TradingView

Jan 24, 2025
pulisher
Jan 24, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 24, 2025
pulisher
Jan 24, 2025

United States shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com India

Jan 24, 2025
pulisher
Jan 23, 2025

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com

Jan 23, 2025
pulisher
Jan 23, 2025

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com UK

Jan 23, 2025
pulisher
Jan 23, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jan 23, 2025
pulisher
Jan 23, 2025

Stock market news: Chanson International Holdings declined by 83.97% while Dogwood Therapeutics surged by 387.32% during mid day trading - Business Upturn

Jan 23, 2025
pulisher
Jan 23, 2025

Stock market today: Icon Energy surged by 222.66% while Jupiter Neurosciences gained over 208.62% in early trading - Business Upturn

Jan 23, 2025
pulisher
Jan 23, 2025

US Stocks Mixed; GE Aerospace Posts Upbeat Earnings - Benzinga

Jan 23, 2025
pulisher
Jan 23, 2025

Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights

Jan 23, 2025
pulisher
Jan 22, 2025

Stock market news: Star Fashion Culture Holdings -78.42%, Lisata Therapeutics -33.08% among biggest losers in early trading - Business Upturn

Jan 22, 2025
pulisher
Jan 22, 2025

Stock market today: Star Fashion Culture Holdings -79.05%, Lisata Therapeutics -23.34% among biggest losers in early trading - Business Upturn

Jan 22, 2025
pulisher
Jan 21, 2025

Twin Vee PowerCats Co. New 5-Axis CNC Router to Harness Advanced Robotics in Production Process - The Globe and Mail

Jan 21, 2025
pulisher
Jan 14, 2025

Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online

Jan 14, 2025

Finanzdaten der Jupiter Neurosciences Inc-Aktie (JUNS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.65
price up icon 0.63%
$70.47
price up icon 1.28%
$32.49
price up icon 0.64%
$23.90
price up icon 1.85%
$108.35
price up icon 3.89%
biotechnology ONC
$247.87
price up icon 1.21%
Kapitalisierung:     |  Volumen (24h):